Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 16/20 | 0.44 |
| ▸ | CHUK | O15111 | 14/20 | 0.44 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591825 | 0.87 | JAK2 (0.47) | IKBKB | |
| SCHEMBL3587149 | 0.83 | IKBKB (0.49) | IKBKBCHUKEGFR | |
| SCHEMBL4622267 | 0.81 | MAPT (0.39) | EGFR | |
| SCHEMBL3590831 | 0.79 | IKBKB (0.53) | IKBKBCHUKEGFR | |
| SCHEMBL4622635 | 0.79 | ACHE (0.42) | — | |
| SCHEMBL4881265 | 0.78 | MEN1 (0.42) | IKBKBCHUK | |
| SCHEMBL4622719 | 0.76 | MEN1 (0.46) | IKBKBCHUKEGFR | |
| Hydrochloric Acid SCHEMBL4883215 | 0.76 | MEN1 (0.45) | IKBKBCHUKEGFR | |
| SCHEMBL4622257 | 0.75 | MEN1 (0.48) | IKBKB | |
| SCHEMBL3594259 | 0.75 | JAK2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069417-A1 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| EP-2111395-A1 | NEW PHENYL- (4-PHENYL-PYRIMIDIN-2-YL) - AMINES DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008099074-A1 | PHENYL- (4-PHENYL-PYRIMIDIN-2-YL) - AMINE DERIVATIVES AS IKK INHIBITORS, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069417-A1 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | IKBKB, NFKBIA, IKBKE | IKBKB 1/4885CHUK 4/4885BRD4 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.